Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.

Li P, Zhang Q, Robichaud AJ, Lee T, Tomesch J, Yao W, Beard JD, Snyder GL, Zhu H, Peng Y, Hendrick JP, Vanover KE, Davis RE, Mates S, Wennogle LP.

J Med Chem. 2014 Mar 27;57(6):2670-82. doi: 10.1021/jm401958n.

PMID:
24559051
2.

Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission.

Snyder GL, Vanover KE, Zhu H, Miller DB, O'Callaghan JP, Tomesch J, Li P, Zhang Q, Krishnan V, Hendrick JP, Nestler EJ, Davis RE, Wennogle LP, Mates S.

Psychopharmacology (Berl). 2015 Feb;232(3):605-21. doi: 10.1007/s00213-014-3704-1.

3.
4.

Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.

Campiani G, Butini S, Fattorusso C, Catalanotti B, Gemma S, Nacci V, Morelli E, Cagnotto A, Mereghetti I, Mennini T, Carli M, Minetti P, Di Cesare MA, Mastroianni D, Scafetta N, Galletti B, Stasi MA, Castorina M, Pacifici L, Vertechy M, Di Serio S, Ghirardi O, Tinti O, Carminati P.

J Med Chem. 2004 Jan 1;47(1):143-57.

PMID:
14695828
6.

In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).

Okuyama S, Chaki S, Yoshikawa R, Suzuki Y, Ogawa S, Imagawa Y, Kawashima N, Ikeda Y, Kumagai T, Nakazato A, Nagamine M, Tomisawa K.

J Pharmacol Exp Ther. 1997 Jul;282(1):56-63.

7.

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.

Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.

J Pharmacol Exp Ther. 1995 Oct;275(1):101-13.

PMID:
7562537
8.
9.

Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.

Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD.

Psychopharmacology (Berl). 2007 Feb;190(3):373-82.

PMID:
17242925
10.

Synthesis and pharmacological evaluation of 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with clozapine-like mixed activities at dopamine D(2), serotonin, and GABA(A) receptors.

Asproni B, Pau A, Bitti M, Melosu M, Cerri R, Dazzi L, Seu E, Maciocco E, Sanna E, Busonero F, Talani G, Pusceddu L, Altomare C, Trapani G, Biggio G.

J Med Chem. 2002 Oct 10;45(21):4655-68.

PMID:
12361392
11.

Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics.

Raviña E, Casariego I, Masaguer CF, Fontenla JA, Montenegro GY, Rivas ME, Loza MI, Enguix MJ, Villazon M, Cadavid MI, Demontis GC.

J Med Chem. 2000 Nov 30;43(24):4678-93.

PMID:
11101359
12.
13.

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.

Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, Rotella D, Feenstra RW, Kruse C, Broqua P, Beyer CE, McCreary AC, Pausch MH, Marquis KL.

J Pharmacol Exp Ther. 2010 Jan;332(1):190-201. doi: 10.1124/jpet.109.157388.

14.

Studies towards the identification of a new generation of atypical antipsychotic agents.

Garzya V, Forbes IT, Gribble AD, Hadley MS, Lightfoot AP, Payne AH, Smith AB, Douglas SE, Cooper DG, Stansfield IG, Meeson M, Dodds EE, Jones DN, Wood M, Reavill C, Scorer CA, Worby A, Riley G, Eddershaw P, Ioannou C, Donati D, Hagan JJ, Ratti EA.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):400-5.

PMID:
17084080
15.

New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.

Liégeois JF, Deville M, Dilly S, Lamy C, Mangin F, Résimont M, Tarazi FI.

J Med Chem. 2012 Feb 23;55(4):1572-82. doi: 10.1021/jm2013419.

PMID:
22268448
16.

Novel, highly potent, selective 5-HT2A/D2 receptor antagonists as potential atypical antipsychotics.

Lee T, Robichaud AJ, Boyle KE, Lu Y, Robertson DW, Miller KJ, Fitzgerald LW, McElroy JF, Largent BL.

Bioorg Med Chem Lett. 2003 Feb 24;13(4):767-70.

PMID:
12639577
17.
18.

Homology modeling of the human 5-HT1A, 5-HT 2A, D1, and D2 receptors: model refinement with molecular dynamics simulations and docking evaluation.

Yap BK, Buckle MJ, Doughty SW.

J Mol Model. 2012 Aug;18(8):3639-55. doi: 10.1007/s00894-012-1368-5.

PMID:
22354276
19.

Synthesis and serotonin 2 (5-HT2) receptor antagonist activity of 5-aminoalkyl-substituted pyrrolo[3,2-c]azepines and related compounds.

Mizuno A, Ogata A, Kamei T, Shibata M, Shimamoto T, Hayashi Y, Nakanishi K, Takiguchi C, Oka N, Inomata N.

Chem Pharm Bull (Tokyo). 2000 May;48(5):623-35.

PMID:
10823697
20.

New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones.

Brea J, Rodrigo J, Carrieri A, Sanz F, Cadavid MI, Enguix MJ, Villazón M, Mengod G, Caro Y, Masaguer CF, Raviña E, Centeno NB, Carotti A, Loza MI.

J Med Chem. 2002 Jan 3;45(1):54-71.

PMID:
11754579
Items per page

Supplemental Content

Support Center